Tag results:

AMPK

Myeloid Ikaros–SIRT1 Signaling Axis Regulates Hepatic Inflammation and Pyroptosis in Ischemia-Stressed Mouse and Human Liver

[Journal of Hepatology] Investigators undertook molecular and functional studies to interrogate the significance of the myeloid Ikaros–SIRT1 axis in the innate immune activation and to determine whether it served as a homeostatic sentinel in hepatic rejuvenation in mouse and human liver.

Ras Inhibitor Farnesylthiosalicylic Acid Conjugated with IR783 Dye Exhibits Improved Tumor-Targeting and Altered Anti-Breast Cancer Mechanisms in Mice

[Acta Pharmacologica Sinica] Investigators demonstrated that organic anion transporting polypeptide and endocytosis synergistically drove the uptake of the farnesylthiosalicylic acid-IR783 conjugate in breast cancer MDA-MB-231 cells, resulting in superior tumor-targeting ability of the conjugate both in vitro and in vivo.

CHK1 Protects Oncogenic KRAS-Expressing Cells from DNA Damage and Is a Target for Pancreatic Cancer Treatment

[Cell Reports] Pharmacologic inhibition of CHK1 alone caused apoptotic growth suppression of both PDAC cell lines and organoids, which correlated with loss of MYC expression.

Ligature Induced Periodontitis in Rats Causes Gut Dysbiosis Leading to Hepatic Injury through SCD1/AMPK Signaling Pathway

[Life Sciences] RNA sequencing of liver tissue showed that the expression of SCD1 increased significantly in chronic periodontitis rats compared to controls. KEGG enrichment analysis showed that the AMPK signalling pathway may have been involved in liver steatosis.

Ad-Apoptin Inhibits Glycolysis, Migration and Invasion in Lung Cancer Cells Targeting AMPK/mTOR Signaling Pathway

[Experimental Cell Research] Researchers investigated the effects of Ad-apoptin on glycolysis, migration and invasion of non-small cell lung cancer.

ACY-241, an HDAC6 Inhibitor, Overcomes Erlotinib Resistance in Human Pancreatic Cancer Cells by Inducing Autophagy

[Archives of Pharmacal Research] Researchers evaluated the anticancer effect of ACY-241, an HDAC6-selective inhibitor, on erlotinib-resistant pancreatic cancer cells that overexpressed HDAC6.

Popular